Development of a recombinant yellow fever vector expressing a HIV clade C founder envelope gp120.

Journal Article (Journal Article)

Development of a HIV-1 vaccine is a major global priority. The yellow fever virus (YFV) attenuated vaccine 17D is among the most effective of currently used vaccines. However, the stability of the YFV17D vector when carrying non-flavivirus genes has been problematic. We have constructed and expressed HIV-1 Env in YFV17D with either single transmembrane (STM) or double transmembrane (DTM) YFV E protein domains for the development of anti-HIV antibodies. Here we describe modifications of the YFV17D vector such that HIV-1 Env gp120 is expressed in up to 5 passages in Vero cells. Immunization with recombinant YFV17D vector prime followed by HIV-1 CH505 TF gp120 protein boosts were able to induce neutralizing antibodies for a HIV-1 tier 1 isolate in mice. This modified YFV vector may be a starting point for constructing HIV-1 vaccine candidate priming vectors.

Full Text

Duke Authors

Cited Authors

  • Yu, J-S; Liao, H-X; Pritchett, J; Bowman, C; Vivian, C; Parks, R; Xia, S-M; Cooper, M; Williams, WB; Bonsignori, M; Reed, SG; Chen, M; Vandergrift, N; Rice, CM; Haynes, BF

Published Date

  • November 2017

Published In

Volume / Issue

  • 249 /

Start / End Page

  • 85 - 93

PubMed ID

  • 28837840

Pubmed Central ID

  • PMC5623118

Electronic International Standard Serial Number (EISSN)

  • 1879-0984

Digital Object Identifier (DOI)

  • 10.1016/j.jviromet.2017.08.012


  • eng

Conference Location

  • Netherlands